Osteogenic Growth Peptide (OGP)
Overview
Osteogenic Growth Peptide is a naturally occurring 14-amino acid peptide identified in serum that promotes osteoblast proliferation and differentiation. The peptide activates the MAP kinase signaling pathway and stimulates collagen synthesis in bone-forming cells.
Mechanism of Action
OGP also demonstrates hematopoietic activity, influencing stem cell differentiation in the bone marrow microenvironment. Synthetic analogs have been developed to enhance stability and receptor affinity for potential therapeutic applications in osteoporosis and fracture healing.
Research Summary & Key Findings
Preclinical studies in ovariectomized rats and other animal models have demonstrated increased bone formation, trabecular connectivity, and bone strength following OGP administration. In vitro experiments confirm dose-dependent stimulation of osteoblast proliferation and alkaline phosphatase activity. No clinical trials in humans have been published, and the peptide remains in preclinical development with ongoing research into optimized delivery systems and dosing regimens.
Clinical Status
Osteogenic Growth Peptide (OGP) is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
Administration Routes
References
Primary literature
- PubMed — "Osteogenic Growth Peptide"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov — "Osteogenic Growth Peptide"
Registered interventional and observational studies, including status and phase.
- PubChem — "Osteogenic Growth Peptide"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Bone
Teriparatide (Forteo)
FDA ApprovedA recombinant form of the first 34 amino acids of human parathyroid hormone (PTH 1-34). When administered intermittently...
View detailsAbaloparatide (Tymlos)
FDA ApprovedA synthetic 34-amino acid peptide analog of parathyroid hormone-related protein (PTHrP 1-34) that selectively activates ...
View detailsCalcitonin
FDA ApprovedA 32-amino acid peptide hormone naturally produced by parafollicular C-cells of the thyroid gland. Calcitonin inhibits o...
View detailsVosoritide (Voxzogo)
FDA ApprovedA C-type natriuretic peptide (CNP) analog that acts as an agonist at the natriuretic peptide receptor B (NPR-B) on growt...
View detailsStart Your Consultation
Get an AI-proposed Osteogenic Growth Peptide (OGP) protocol reviewed by a physician in our network.
Start Your ConsultationFind a Pharmacy
Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Osteogenic Growth Peptide (OGP).
Pharmacy DirectoryJoin the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.